Abstract
An ATM-dependent cellular signal, a DNA-damage response, has been shown to be involved during infection of human immunodeficiency virus type-1 (HIV-1), and a high incidence of malignant tumor development has been observed in HIV-1-positive patients. Vpr, an accessory gene product of HIV-1, delays the progression of the cell cycle at the G2/M phase, and ATR–Chk1-Wee-1, another DNA-damage signal, is a proposed cellular pathway responsible for the Vpr-induced cell cycle arrest. In this study, we present evidence that Vpr also activates ATM, and induces expression of γ-H2AX and phosphorylation of Chk2. Strikingly, Vpr was found to stimulate the focus formation of Rad51 and BRCA1, which are involved in repair of DNA double-strand breaks (DSBs) by homologous recombination (HR), and biochemical analysis revealed that Vpr dissociates the interaction of p53 and Rad51 in the chromatin fraction, as observed under irradiation-induced DSBs. Vpr was consistently found to increase the rate of HR in the locus of I-SceI, a rare cutting-enzyme site that had been introduced into the genome. An increase of the HR rate enhanced by Vpr was attenuated by an ATM inhibitor, KU55933, suggesting that Vpr-induced DSBs activate ATM-dependent cellular signal that enhances the intracellular recombination potential. In context with a recent report that KU55933 attenuated the integration of HIV-1 into host genomes, we discuss the possible role of Vpr-induced DSBs in viral integration and also in HIV-1 associated malignancy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abraham RT . (2001). Genes Dev 15: 2177–2196.
Anglana M, Bacchetti S . (1999). Nucleic Acids Res 27: 4276–4281.
Bartz SR, Rogel ME, Emerman M . (1996). J Virol 70: 2324–2331.
Bertrand P, Saintigny Y, Lopez BS . (2004). Trends Genet 20: 235–243.
Biggar RJ, Rosenberg PS, Coté T, Multistate AIDS/Cancer Match Study Group. (1996). Int J Cancer 68: 754–758.
Brown EJ, Baltimore D . (2003). Genes Dev 17: 615–628.
Bukrinsky M, Adzhubei A . (1999). Rev Med Virol 9: 39–49.
Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K et al. (2005). Cancer 104: 1505–1511.
Chadburn A, Cesarman E, Knowles DH . (1997). Semin Diagn Pathol 14: 15–26.
Cromie GA, Connelly JC, Leach DRF . (2001). Mol Cell 8: 1163–1174.
Daniel R, Greger JG, Katz RA, Taganov KD, Wu X, Kappes JC et al. (2004). J Virol 78: 8573–8581.
Daniel R, Kao G, Tagarov K, Greger JG, Favorova O, Merkel G et al. (2003). Proc Natl Acad Sci USA 100: 4778–4783.
Daniel R, Katz RA, Skalka AM . (1999). Science 284: 644–647.
Daniel R, Marusich E, Argyris E, Zhao RY, Skalka AM, Pomerantz RJ . (2005). J Virol 79: 2058–2065.
Dong Y, Hakimi MA, Chen X, Kumaraswamy E, Cooch NS, Godwin AK et al. (2003). Mol Cell 12: 1087–1099.
Elder RT, Benko Z, Zhao Y . (2002). Front Biosci 7: d349–d357.
Elenitoba-Johnson KS, Jaffe ES . (1997). Semin Diagn Pathol 14: 35–47.
Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA et al. (1998). Nat Med 4: 65–71.
Groschel B, Bushman F . (2005). J Virol 79: 5695–5704.
He J, Choe S, Walker R, Di Marzio PD, Morgan DO, Landau NR . (1995). J Virol 69: 6705–6711.
Henklein P, Bruns K, Sherman M P, Tessmer U, Licha K, Kopp J et al. (2000). J Biol Chem 275: 32016–32026.
Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin IP, Rabaud C et al. (2003). J Clin Oncol 21: 3447–3453.
Hoshino S, Sun B, Shimura M, Konishi M, Taguchi T, Segawa T et al. (2006). submitted.
Huang M-B, Weeks O, Zhao L-J, Saltarelli M, Bond VC . (2000). J Neuro Viol 6: 202–220.
Huang X, Kurose A, Tanaka T, Traganos F, Dai W, Darzynkiewicz Z . (2006). Cytometer A 69A: 222–229.
Ishizaka Y, Chernov MV, Burns CM, Stark GR . (1995). Proc Natl Acad Sci USA 92: 3224–3228.
Yamaguchi-Iwai Y, Sonoda E, Buerstedde J-M, Bezzubova O, Morrison C, Takata M et al. (1998). Mol Cell Biol 18: 6430–6435.
Jeanson L, Subra F, Vaganay S, Hervy M, Marangoni E, Bourhis J et al. (2002). Virology 300: 100–108.
Jenkins Y, McEntee M, Weis K, Greene WC . (1998). J Cell Biol 143: 875–885.
Kagawa W, Kurumizaka H, Ikawa S, Yokoyama S, Shibata T . (2001). J Biol Chem 276: 35201–35208.
Khanna KK, Jackson SP . (2001). Nat Genet 27: 247–254.
Khanna KK, Lavin MF, Jackson SP, Mulhern TD . (2001). Cell Death Differ 8: 1052–1065.
Knowles DM . (2003). Hematol Oncol Clin N Am 17: 785–820.
Kurumizaka H, Aihara H, Kagawa W, Shibata T, Yokoyama S . (1999). J Mol Biol 291: 537–548.
Lai M, Zimmerman ES, Planelles V, Chen J . (2005). J Virol 79: 15443–15451.
Lau A, Kanaar R, Jackson SP, O'Connor MJ . (2004). EMBO J 23: 3421–3429.
Lau A, Swinbank KM, Ahmed PS, Taylor DL, Jackson SP, Smith GCM et al. (2005). Nat Cell Biol 7: 493–500.
Laurence J, Astrin SM . (1991). Proc Natl Acad Sci USA 88: 7635–7639.
Levy DN, Refaeli Y, MacGregor RR, Weiner DB . (1994). Proc Natl Acad Sci USA 91: 10873–10877.
Li L, Olvera JM, Yoder KE, Mitchell RS, Butler SL, Lieber M et al. (2001). EMBO J 20: 3272–3281.
Lim ST, Levine AM . (2005). Curr HIV/AIDS Rep 2: 146–153.
Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S et al. (2003). Cancer Res 63: 2596–2605.
Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Kao GD, Muschel RJ et al. (1998). Proc Natl Acad Sci USA 95: 3419–3424.
Marmorstein LY, Ouchi T, Aaronson SA . (1998). Proc Natl Acad Sci USA 95: 13869–13874.
Mayer V, Ebbesen P, Zachar V . (1995). Eur J Cancer Prev 4: 211–212.
Nunnari G, Argyris E, Fang J, Mehlman KE, Pomerantz RJ, Daniel R . (2005). Virology 335: 177–184.
O'Connell MJ, Walworth NC, Carr AM . (2000). Trends Cell Biol 10: 296–303.
Pierce AJ, Johnson RD, Thompson LH, Jasin M . (1999). Gene Dev 13: 2633–2638.
Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V . (2003). J Biol Chem 278: 25879–25886.
Sawaya BE, Khalili K, Mercer WE, Denisova L, Amini S . (1998). J Biol Chem 273: 20052–20057.
Sengupta S, Linke SP, Pedeux R, Yang Q, Farnsworth J, Garfield SH et al. (2003). EMBO J 22: 1210–1222.
Shiloh Y . (2001). Curr Opin Genet Dev 11: 71–77.
Shimura M, Onozuka Y, Yamaguchi T, Hatake K, Takaku F, Ishizaka Y . (1999a). Cancer Res 59: 2259–2264.
Shimura M, Tanaka Y, Nakamura S, Minemoto Y, Yamashita K, Hatake K et al. (1999b). FASEB J 13: 621–637.
Shimura M, Tokunaga K, Konishi M, Sato Y, Kobayashi C, Sata T et al. (2005). AIDS 19: 1434–1438.
Slebos RC, Taylor JA . (2001). Biochem Biohpys Res Commun 281: 212–219.
Straus DJ . (2001). Curr Oncol Rep 3: 260–265.
Tachiwana H, Shimura M, Nakai-Murakami C, Tokunaga K, Takizawa Y, Sata T et al. (2006). Cancer Res 66: 627–631.
Taguchi T, Shimura M, Osawa Y, Suzuki Y, Mizoguchi I, Niino K et al. (2004). Biochem Biophys Res Commun 320: 18–26.
Tokunaga K, Greenberg ML, Morse MA, Cumming RI, Lyerly HK, Cullen BR . (2001). J Virol 75: 6776–6785.
van Gent DC, Hoeijmakers JHJ, Kanaar R . (2001). Nat Rev Genet 2: 196–206.
Waldman AS, Liskay RM . (1987). Proc Natl Acad Sci USA 84: 5340–5344.
West SC . (2003). Nat Rev Mol Cell Biol 4: 1–11.
Yoon D, Wang Y, Stapleford K, Wiesmüller L, Chen J . (2004). J Mol Biol 336: 639–654.
Yuan H, Kamata M, Xie Y-M, Chen ISY . (2004). J Virol 78: 8183–8190.
Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL et al. (1998). Oncogene 16: 1713–1721.
Zimmerman ES, Chen J, Andersen JL, Ardon O, DeHart JL, Blackett J et al. (2004). Mol Cell Biol 24: 9286–9294.
Acknowledgements
We are grateful to Dr T Takemori (National Institute of Infectious Diseases, Japan) to help for analysis by a Vantage flow cytometer. We also thank to Riken BRC for control adenovirus, AxCALac8, and HT1080 cells. Drs Slebos (National Institute of Environmental Health Science, USA), Jasin M (Memorial Sloan-Kettering Cancer Center, USA), Graham F (McMaster University, Canada), and Saito I (Institute of Medical Sciences, of Tokyo University, Japan) kindly provided us with pBHRF, pDR-GFP, adenovirus of I-SceI, and AxCALac8, respectively. We also thank to O'Connor M (KuDOS pharmaceuticals, England) for KU55933. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labor and a Grant for research on Health Sciences focusing on Drug Innovation. Dr Nakai-Murakami is a research resident supported by the Japan Health Sciences Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Nakai-Murakami, C., Shimura, M., Kinomoto, M. et al. HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene 26, 477–486 (2007). https://doi.org/10.1038/sj.onc.1209831
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209831
Keywords
This article is cited by
-
Impact of HIV-1 Vpr manipulation of the DNA repair enzyme UNG2 on B lymphocyte class switch recombination
Journal of Translational Medicine (2020)
-
Structural alteration of DNA induced by viral protein R of HIV-1 triggers the DNA damage response
Retrovirology (2018)
-
MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins
Nature Medicine (2015)
-
DNA repair mechanisms and human cytomegalovirus (HCMV) infection
Folia Microbiologica (2015)
-
Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest
Virology Journal (2014)